NKGen Biotech (NYSE:NKGN) Trading Up 9.5% – Time to Buy?

NKGen Biotech, Inc. (NYSE:NKGN) was up 9.5% during trading on Tuesday . The company traded as high as $0.48 and last traded at $0.48. Approximately 221,532 shares traded hands during trading, a decline of 22% from the average daily volume of 283,682 shares. The stock had previously closed at $0.44.

NKGen Biotech Stock Performance

The stock has a 50 day moving average of $0.50 and a two-hundred day moving average of $0.62. The firm has a market capitalization of $17.04 million, a P/E ratio of -0.09 and a beta of 0.53.

Institutional Trading of NKGen Biotech

An institutional investor recently raised its position in NKGen Biotech stock. Sequoia Financial Advisors LLC boosted its holdings in NKGen Biotech, Inc. (NYSE:NKGN) by 273.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 69,000 shares of the company’s stock after acquiring an additional 50,500 shares during the quarter. Sequoia Financial Advisors LLC owned 0.27% of NKGen Biotech worth $26,000 at the end of the most recent quarter. 76.17% of the stock is owned by institutional investors and hedge funds.

About NKGen Biotech

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.